You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

25 Results
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Palliative
Apr 2018
Regimen
Cancer Type:
Sarcoma, 
Kaposi's Sarcoma
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Sarcoma, 
Ewing's
Intent: Neoadjuvant, Adjuvant, Palliative
May 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Sep 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Palliative
Jun 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Nov 2019
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) in combination with Chemotherapy - Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
May 2024
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Funding:
Exceptional Access Program
    vanDETanib - Monotherapy for symptomatic and/or progressive medullary thyroid cancer (MTC), with specific criteria
Nov 2023
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    vemURAFenib - Monotherapy in patients with BRAF V600 mutation-positive unresectable stage Ill or stage IV melanoma, with specific criteria
Aug 2023
Regimen
Cancer Type:
Skin, 
Basal Cell
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vismodegib - Treatment for metastatic basal cell carcinoma (BCC) or with locally advanced BCC (including patients with basal cell nevus syndrome, i.e. Gorlin syndrome), according to specific criteria
Aug 2023
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Aug 2017
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Oct 2017

Pages